Ac-LKKTETQ comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-13. Numbers and descriptions here follow the published literature rather than marketing material.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Dr. Gian Parkash Gopal. Founder, Oxford Hindu Temple and Community Centre Project. For services to the Hindu Community and to Multi-Faith Cohesion in Oxfordshire. Elizabeth Jane Gorb. Director of Apprenticeships, Manchester Metropolitan University. For services to Education and Skills. Permjit Gosal (Pam Gosal), MSP. Member of the Scottish Parliament for West Scotland. For services to Business, to Racial Equality and to Charity in Milton Keynes. David James Connelly Graham. National Director, Care Leavers Association. For services to Care Leavers. Sarah Jane Vandevelde Graham. Founder, Hilltops Ukrainian Support Community. For services to Ukrainian Refugees. The Reverend Canon Terence Kevin Declan Graham, DL. Rector, St Bartholomew's Church, Belfast. For services to the Reserve Forces and to the community in Belfast. Julie Grant. Deputy Director, News and Digital, Scottish Government. For services to Scotland on the Demise of Her Majesty Queen Elizabeth II. Dr. Simon Jonathon Grant. Technical Director, Thomas Swan. For services to Diversity in the Chemical Industry. Belinda Elizabeth Gray. Founder, Art for Cure. For services to Breast Cancer Charities. Julie Heather Gray. Founder, Adventure Activities for All Abilities. For services to Children with Impairments in Nottinghamshire. Neil Jonathan Greenwood. Executive Director, Finance and Corporate Services, Natural History Museum. For services to Museums. Robert Terence Grey. Lately Boxing Gym Owner and Trainer, Gwent Amateur Boxing Club. For services to Amateur Boxing in Swansea. Dr. John Michael Grimshaw.
During the retention period, specimens are considered part of the medical record and must be kept in a CLIA-accredited laboratory to ensure compliant handling and storage conditions. If a specimen is sent out to a non-CLIA biorepository and recalled, the additional testing would not be in compliance. There is an effort to make more biobanks CLIA equivalent as specimen recalls become more common due to expanded testing.
== Side effects == Side effects of etifoxine include slight drowsiness and headache. Rarely, etifoxine can cause benign skin eruptions or rashes and allergic reactions such as hives and angioedema. Etifoxine shows less adverse effects of anterograde amnesia, sedation, impaired psychomotor performance, and withdrawal syndromes than those of benzodiazepines. No cases of misuse or dependence with etifoxine were identified in a French pharmacovigilance survey, which is also in contrast to benzodiazepines. Etifoxine has been associated rarely with cases of severe dermal toxicity and liver toxicity. Skin and subcutaneous disorders are the most frequently reported, but these generally resolve after drug cessation. A 2012 review of etifoxine by the French National Pharmacovigilance Committee determined that etifoxine was safe and continued to provide a favorable alternative to benzodiazepine anxiolytics. The committee found (for a ten-year pharmacovigilance period) that safety concerns were rare or very rare and that the incidence of idiosyncratic hepatic (liver) problems were very rare.
The compound is now under active investigation by researchers at NIMH for potential clinical use, and it is hoped that use of HNK instead will mitigate the various concerns (such as abuse and dissociation) of using ketamine itself in the treatment of depression.
Sources: en.wikipedia.org
==== Distribution ==== Trazodone is not sequestered into any tissue. The medication is 89 to 95% protein-bound. The volume of distribution of trazodone is 0.8 to 1.5 L/kg. Trazodone is highly lipophilic.
In 2002, Israel Prize In 2005, Louisa Gross Horwitz Prize In 2006, Wolf Prize in Chemistry along with George Feher. In 2006, The EMET Prize for Art, Science and Culture in Life Sciences, along with Professor Peretz Lavie (Medicine) and Professor Eli Keshet (Biology) In 2007, Paul Ehrlich and Ludwig Darmstaedter Prize along with Harry Noller In 2008, the Albert Einstein World Award of Science for her pioneering contributions to protein biosynthesis in the field of ribosomal crystallography and her introduction of innovative techniques in cryo bio-crystallography. In 2009, the Nobel Prize in Chemistry (co-recipient with Thomas Steitz and Venkatraman Ramakrishnan). She was the first Israeli woman to be awarded a Nobel Prize. In 2010, Wilhelm Exner Medal In 2011, Marie Curie Medal awarded by the Polish Chemical Society In 2013 she became a member of the German Academy of Sciences Leopoldina. In 2015, she was awarded Honorary Doctorates from the University of Southern California, the De La Salle University, Manila/Philippines; the Joseph Fourier University, Grenoble/France; the Medical University of Lodz, Lodz/Poland; and the University of Warwick, UK. In 2018, Elizabeth Cabezas, President of the Ecuadorian National Assembly, presented Yonath with the Presea "Asamblea Nacional de la República del Ecuador, Dra. Matilde Hidalgo de Procel" (National Assembly of Ecuador Dr. Matilde Hidalgo de Procel Medal) for scientific merit.
Size-exclusion chromatography, also known as molecular sieve chromatography, is a chromatographic method in which molecules in solution are separated by their shape, and in some cases size. It is usually applied to large molecules or macromolecular complexes such as proteins and industrial polymers. Typically, when an aqueous solution is used to transport the sample through the column, the technique is known as gel filtration chromatography, versus the name gel permeation chromatography, which is used when an organic solvent is used as a mobile phase. The chromatography column is packed with fine, porous beads which are commonly composed of dextran, agarose, or polyacrylamide polymers. The pore sizes of these beads are used to estimate the dimensions of macromolecules. SEC is a widely used polymer characterization method because of its ability to provide good molar mass distribution (Mw) results for polymers. Size-exclusion chromatography (SEC) is fundamentally different from all other chromatographic techniques in that separation is based on a simple procedure of classifying molecule sizes rather than any type of interaction.
=== Postdrome === The migraine postdrome, sometimes referred to as the "migraine hangover", is the collection of symptoms that occur after the acute headache has ceased. The International Classification of Headache Disorders (ICHD-3) defines this as the 48 hours after the pain ceases. Common symptoms include tiredness, difficulty concentrating, mood changes, and thirst. Other symptoms reported include dizziness and euphoria.
== History == A 13th century manuscript by Ibn Nafis contains the earliest known description of capillaries. The manuscript records Ibn Nafis' prediction of the existence of the capillaries which he described as perceptible passages (manafidh) between pulmonary artery and pulmonary vein. These passages would later be identified by Marcello Malpighi as capillaries. He further states that the heart's two main chambers (right and left ventricles) are separate and that blood cannot pass through the (interventricular) septum. William Harvey did not explicitly predict the existence of capillaries, but he saw the need for some sort of connection between the arterial and venous systems. In 1653, he wrote, "...the blood doth enter into every member through the arteries, and does return by the veins, and that the veins are the vessels and ways by which the blood is returned to the heart itself; and that the blood in the members and extremities does pass from the arteries into the veins (either mediately by an anastomosis, or immediately through the porosities of the flesh, or both ways) as before it did in the heart and thorax out of the veins, into the arteries..." Marcello Malpighi was the first to observe directly and correctly describe capillaries, discovering them in a frog's lung 8 years later, in 1661. August Krogh discovered how capillaries provide nutrients to animal tissue. For his work he was awarded the 1920 Nobel Prize in Physiology or Medicine.
Sources: en.wikipedia.org
Brazzein is a sweet-tasting protein that occurs naturally in oubli (Pentadiplandra brazzeana), a fruit native to the Atlantic coastal areas of Central Africa. Brazzein was named in 1994 by scientists at the University of Wisconsin–Madison. It is roughly 500 to 2000 times sweeter than sucrose. Brazzein is found in the extracellular region of oubli fruit, in the pulp tissue surrounding the seeds. It was first discovered and isolated in 1989 by Wel et al. under the name of pentadin. The corresponding author of both these publications has later opined that pentadin and brazzein are two different names for the same protein. Even though pentadin is the earlier proposed name, brazzein is the more commonly used name after more extensive characterisation of the sweet protein. Like other sweet proteins discovered in plants, such as monellin and thaumatin, brazzein is extremely sweet compared to commonly used sweeteners. The fruit tastes sweet to humans, monkeys, and bonobos, but gorillas have mutations in their sweetness receptors so that they do not find brazzein sweet, and they are not known to eat the fruit.
Some bats prey on other vertebrates, such as fish, frogs, lizards, birds and mammals. The fringe-lipped bat (Trachops cirrhosus), for example, is skilled at catching frogs, locating them by tracking their mating calls. The greater noctule bat (Nyctalus lasiopterus) hunts and catches birds in flight. Some species, like the greater bulldog bat (Noctilio leporinus), hunt fish, flying over the water and grabbing them with their clawed feet. They use echolocation and may be alerted by ripples on the surface or a jumping fish. Some species feed on other bats, including the spectral bat (Vampyrum spectrum) and the ghost bat (Macroderma gigas).
Furthermore, possible recognition sequences for furin (a major physiological protease) cleavage sites have been found in both amino-terminal NC1 domain and carboxyl-terminal NC4 domain of each one of these collagens. The activity of this protease is vital to explain the origin of the two forms that collagen types XIII, XXIII and XXV can adopt.
Kirk Sorensen, former NASA scientist and chief nuclear technologist at Teledyne Brown Engineering, has long been a promoter of thorium fuel cycle and particularly liquid fluoride thorium reactors. In 2011, Sorensen founded Flibe Energy, a company aimed to develop 20–50 MW LFTR reactor designs to power military bases. In October 2010 GE Hitachi Nuclear Energy signed a memorandum of understanding with the operators of the US Department of Energy's Savannah River Site, which should allow the construction of a demonstration plant based on the company's S-PRISM fast breeder reactor prior to the design receiving full Nuclear Regulatory Commission licensing approval. In October 2011 The Independent reported that the UK Nuclear Decommissioning Authority (NDA) and senior advisers within the Department for Energy and Climate Change (DECC) had asked for technical and financial details of PRISM, partly as a means of reducing the country's plutonium stockpile. The traveling wave reactor proposed in a patent by Intellectual Ventures is a fast breeder reactor designed to not need fuel reprocessing during the decades-long lifetime of the reactor. The breed-burn wave in the TWR design does not move from one end of the reactor to the other but gradually from the inside out. Moreover, as the fuel's composition changes through nuclear transmutation, fuel rods are continually reshuffled within the core to optimize the neutron flux and fuel usage at any given point in time.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.